Promising Drug Targets Hyperactivity in Autism Spectrum Disorder

Recent research from Stanford Medicine has identified hyperactivity in the reticular thalamic nucleus (RT) as a significant contributor to autism spectrum disorder (ASD) behaviors in a mouse model. The study, published in *Science Advances*, highlights how this brain region, which regulates sensory information, exhibits elevated activity during social interactions and exposure to stimuli, leading to symptoms such as seizures, repetitive behaviors, and social withdrawal. By administering the experimental drug Z944, which is currently under investigation for epilepsy treatment, researchers successfully reversed these autism-like symptoms in the genetically modified Cntnap2 knockout mice.

Neuroscience NewsDaily MailStanford Researchers Use Epilepsy Drugs to Reverse Autism-Like Symptoms in MiceTechnology Networks

The study revealed that the RT in Cntnap2 knockout mice displayed increased spontaneous activity and susceptibility to seizures. This hyperactivity was linked to the observed behavioral deficits characteristic of autism, including heightened sensitivity to sensory input and reduced social engagement. The researchers employed both pharmacological and chemogenetic approaches to suppress RT activity. Z944, a T-type calcium channel blocker, effectively reduced hyperactivity and improved social preferences in the mice. Additionally, chemogenetic techniques allowed for precise modulation of RT neuron activity, further confirming the region's role in ASD behaviors.

Technology NetworksNeuroscience NewsDaily MailStanford Researchers Use Epilepsy Drugs to Reverse Autism-Like Symptoms in Mice

The findings suggest a shared neurobiological mechanism between autism and epilepsy, with approximately 30% of individuals with autism also experiencing epilepsy, compared to just 1% of the general population. This overlap indicates that treatments targeting the RT may benefit both conditions. The study's authors propose that Z944 could potentially be repurposed for autism treatment, pending further research to explore its efficacy in human subjects.

Daily Mail

While the study presents promising results, it also raises questions about the applicability of these findings to the broader autistic population, particularly those without epilepsy or intellectual disabilities. Future research is needed to investigate the developmental timeline of RT hyperactivity and its potential as an early intervention target. Longitudinal studies and testing across various autism models will be essential to validate these findings and develop circuit-specific interventions.

Technology Networks

John Huguenard, PhD, the senior author of the study, emphasized the significance of these findings, stating, "If this represents a common mechanism underlying ASD circuit pathology across diverse genetic backgrounds, then compounds such as Z944 may offer an effective therapeutic strategy." The research team advocates for continued exploration of RT-mediated circuit dynamics to enhance understanding of ASD and inform future treatment approaches.

Technology Networks

• “Both Z944-mediated pharmacological inhibition and DREADD-based neuromodulation of RT neurons offer a powerful and targeted approach to ameliorate ASD-related behaviors,” — Sung-Soo Jang, PhD, Lead Author

Technology Networks

• “Future research should aim to elucidate how RT-mediated circuit dynamics throughout the brain influence the broader neurobehavioral landscape of ASD,” — Research Team

Technology Networks

This research underscores the potential for innovative treatments targeting specific brain circuits in addressing the complexities of autism spectrum disorder and its comorbidities.

Neuroscience News